All In Biotech

Drug Trial Radar · NCT07297914

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 7, 2026

Primary completion

Nov 30, 2032

Study completion Dec 1, 2032

Sponsor

Lead sponsor
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT). HSCT remains a cornerstone of therapy, offering curative potential; however, it is associated with considerable risks, including non-relapse mortality (NRM), significant morbidity, and long-term complications that continue to be major concerns. In response to these challenges, the FORUM consortium has made substantial progress in improving outcomes for children with ALL undergoing HSCT. The consortium focuses on reducing life-threatening and lifelong complications, ultimately aiming to enhance quality of life for these high-risk patients. Building on the robust evidence generated by FORUM1, the FORUM2 study has been designed to further optimize the role of HSCT in ALL across all age groups and donor settings within a harmonized and internationally coordinated framework. The FORUM2 study introduces a master protocol structure that encompasses multiple hypothesis-driven substudies, each addressing a specific determinant of HSCT outcomes. This design enables simultaneous or sequential evaluation of novel strategies while ensuring uniform governance, endpoint definitions, and data-quality standards. The overarching objective is to refine the role of HSCT in ALL by reducing treatment-related toxicity while preserving the essential graft-versus-leukemia effect.

Conditions

  • Acute Lymphoblastic Leukemia (ALL)
  • Stem Cell Transplant
  • Graft -Versus-host-disease

Interventions

  • Total Body Irradiation 8 GyRadiation

    Total Body Irradiation 8 Gy administered in combination with VP16 as part of the conditioning regimen

  • RuxolitinibCombination product

    Ruxolitinib plus corticosteroids in treatment-naïve acute graft-versus-host disease

  • BlinatumomabDrug

    Up to four cycles of blinatumomab as post-HSCT maintenance therapy

  • CyclophosphamideDrug

    In vivo T-cells depletion/modulation with post-transplant cyclophosphamide

  • Total Body Irradiation 12 GyRadiation

    Total Body Irradiation 12 Gy administered in combination with VP16 as part of the conditioning regimen

  • CorticosteroidsDrug

    Corticosteroids alone in treatment-naïve acute graft-versus-host disease

  • αβ T-cells depletionOther

    Ex vivo graft manipulation based on selective depletion of T-cell receptor αβ (TCR αβ+)/CD19+ lymphocytes from the graft (αβ T-cells depletion)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (EFS)Time frame: at year 4
  2. Overall response rate (ORR) at day 28Time frame: day 28
  3. Event Free Survival (EFS)Time frame: at year 4
  4. Cumulative incidence of relapse (CIR) at 2 years after HSCTTime frame: 2 years after HSCT

Locations

9 sites in 9 countries. Site status is shown where the registry gives one.

  • St'Anna Children Hospital

    Vienna, Austria · Not yet recruiting

  • University Hospital Motol

    Prague, Czechia · Recruiting

  • Rigshopsitalet, University Hospital

    Copenhagen, Denmark · Not yet recruiting

  • HUS-Yhtymae (HUS Helsinki University Hospital)

    Helsinki, Finland · Not yet recruiting

  • Robert- Debré Academic Hospital

    Paris, France · Not yet recruiting

  • Goethe-Universität

    Frankfurt, Germany · Recruiting

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, RM, Italy · Not yet recruiting

  • University Hospital

    Oslo, Norway · Active not recruiting

  • University of Medical Sciences

    Poznan, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.